Prenetics Global (NASDAQ: PRE) recently disclosed record financial results for the fourth quarter and full year of fiscal 2025.

Its core business line, IM8, achieved an annualized revenue (ARR) of $120 million within just 12 months, demonstrating strong growth momentum. Even more remarkable, the company’s overall revenue increased by 480% year-on-year, reflecting the tremendous potential of its business model and effective market expansion strategies. This outstanding performance is attributed to the company’s continuous innovation and strategic execution in the field of precision medicine, marking a key step for Prenetics in advancing global health solutions.